Gara Jalqabaatti › Melanoma › New York › New York City
Qorannoo klinikaalii Melanoma New York City, NY keessatti
Qorannoo 38 Melanoma f New York City fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Memorial Sloan Kettering (Melanoma/NSCLC), New York
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 2
- Memorial Sloan Kettering Hospital, New York
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Namoota walitti qabaa jiraSadarkaa 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
Namoota walitti qabaa jiraSadarkaa 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade
Namoota walitti qabaa jira
- Weill Cornell Medicine, New York
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Namoota walitti qabaa jiraSadarkaa 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Namoota walitti qabaa jiraSadarkaa 2
- Local Institution - 0170, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma
Namoota walitti qabaa jiraSadarkaa 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- NYU Langone, New York
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Memorial Sloan Kettering Hospital, New York
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients
Namoota walitti qabaa jiraSadarkaa 2
- Memorial Sloan Kettering Cancer Center, New York
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Namoota walitti qabaa jira
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Project: Every Child for Younger Patients With Cancer
Namoota walitti qabaa jiraQorannoo ilaalaa
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Mount Sinai Hospital, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- fi 2 dabalataa
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
Namoota walitti qabaa jiraSadarkaa 2
- NYU Langone Health, New York
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Weill Cornell Medicine - New York Presbyterian Hospital, New York
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Namoota walitti qabaa jiraSadarkaa 1/2
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Namoota walitti qabaa jiraSadarkaa 1/2
- Call for Information (Investigational Site 0031), New York
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- Weill Medical College of Cornell University, New York
- Memorial Sloan Kettering Cancer Center, New York
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 2
- USA04-0, New York
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Namoota walitti qabaa jiraSadarkaa 1/2
- Perlmutter Cancer Center at NYU Langone Health, New York
- Memorial Sloan-Kettering Cancer Center, New York
- Columbia University, New York
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Memorial Sloan Kettering Cancer Center, New York
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Namoota walitti qabaa jiraSadarkaa 3
- Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center - 1275 York Ave, New York
- Northwell Health Cancer Institute, New York
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Columbia University Medical Center, New York
- Memorial Slone Kettering Cancer Center, New York
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Namoota walitti qabaa jiraSadarkaa 2/3
- Memorial Sloan Kettering Cancer Center, New York
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Namoota walitti qabaa jiraSadarkaa 3
- Memorial Sloan Kettering Cancer Center, New York
ACTengine® IMA203 Combined With mRNA-4203
Namoota walitti qabaa jiraSadarkaa 1
- Memorial Sloan Kettering Cancer Center, New York
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
Namoota walitti qabaa jiraSadarkaa 2
- NYU Langone Health, New York
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site 107, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Namoota walitti qabaa jiraQorannoo ilaalaa
- Massive Bio SYNERGY-AI site, New York
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
Namoota walitti qabaa jira
- Memorial Sloan Kettering Cancer Center, New York
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Weill Cornell Medicine-New York-Presbyterian Hospital, New York
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- NYU Langone Health, New York
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Namoota walitti qabaa jira
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Namoota walitti qabaa jiraSadarkaa 1/2
- Memorial Sloan-Kettering Cancer Center, New York
Qorannoo Melanoma magaalota biroo keessatti
- Houston, TXQorannoo 59
- Los Angeles, CAQorannoo 34
- Nashville, TNQorannoo 33
- Pittsburgh, PAQorannoo 31
- Boston, MAQorannoo 26
- Philadelphia, PAQorannoo 23
- San Francisco, CAQorannoo 22
- Columbus, OHQorannoo 21
- Durham, NCQorannoo 21
- Atlanta, GAQorannoo 21
- Salt Lake City, UTQorannoo 21
- St. Louis, MOQorannoo 21
Qorannoo biroo New York City keessatti
- Saree OljooQorannoo 136
- Kansara Qara'a Non-Small CellQorannoo 121
- Saree (Gosoota Hunda)Qorannoo 109
- Kansarii ProstateQorannoo 103
- Kansara MetastatikiiQorannoo 93
- Kansarii ColorectalQorannoo 78
- Kansarii OvariiQorannoo 69
- Dhibee QaraQorannoo 60
- Myeloma Baay’eeQorannoo 60
- Kansarii PancreasQorannoo 60
- Kansa EndometiriyaaliiQorannoo 52
- Leukemia Myeloidii HamaaQorannoo 51
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.